Laboratorio Reig Jofre

RJF.MC

Spain· Est. 1929

reigjofre.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

RJF.MC · Stock Price

EUR 2.77+0.29 (+11.69%)

Market Cap: $266.6M

Historical price data

Overview

Founded in 1929, Laboratorio Reig Jofre is a publicly traded Spanish pharmaceutical company on a mission to 'universalize essential health solutions.' Its strategy is built on vertical integration, advanced sterile manufacturing capabilities, and proprietary drug delivery technologies like CicloTech®. Key achievements include strategic investments in biotech manufacturing (Leanbio), a European Commission vaccine capacity reservation, and a growing international commercial footprint across Europe and Asia.

DermatologyHospital/InjectablesWellness/OTC

Technology Platform

Vertically integrated advanced manufacturing for sterile injectables and biologics, combined with the proprietary CicloTech® trans-ungual drug delivery platform for topical nail treatments.

Funding History

IPOUndisclosedUndisclosedJun 15, 1998

Opportunities

The company is positioned to capitalize on the growing markets for complex sterile injectables and biosimilars through its advanced manufacturing and Leanbio investment.

Its EU vaccine capacity agreement provides a strategic, non-cyclical revenue opportunity and validates its production capabilities on a continental scale.

Risk Factors

Reig Jofre faces intense pricing pressure in the generic drug market and significant execution risks associated with its new vertical integration into complex biologics manufacturing.

Its relatively small market cap also makes it susceptible to high stock volatility and potentially limits access to capital.

Competitive Landscape

Competes with global generic giants (Teva, Sandoz) and European peers on cost, while differentiating through vertical integration, sterile manufacturing expertise, and the proprietary CicloTech® platform. The move into biologics via Leanbio introduces competition with large, established biosimilar developers.